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CYP2D6 activity derive inferior therapeutic benefit from tamoxifen, andmay alter-
natively be treated with newer aromatase inhibitors (AIs). However, the high costs
of AIs provide incentive for identifying patients who will benefit from tamoxifen
prior to treatment. We estimated the cost-effectiveness of genetic testing in com-
bination with hormone therapy for early breast cancer in Canada. METHODS:We
performed a cost-effectiveness analysis using a Markov model from a societal per-
spective and a lifetime horizon. The base case assumed 40-year-old ER hormone
sensitive women with early breast cancer. We evaluated: genetic testing with sub-
sequent treatment based on genetic status (tamoxifen for CYP2D6 extensive me-
tabolizers and AIs for decreased metabolizers) vs. no testing (tamoxifen for all
patients). Probabilistic sensitivity analysis was used to incorporate parameter un-
certainties. Expected value of perfect informationwas performed to identify future
research directions. Outcomes were quality-adjusted life years (QALYs) and costs.
RESULTS: The genetic testing and treatment combination strategy resulted in a
2.87 QALY gain when compared to no testing. The incremental cost was CAD
$25,661 compared to standard care, and the incremental cost-effectiveness ratio
(ICER) for the base case was $8,927 per QALY. The ICER was sensitive to disease
progression among intermediate metabolizers, and costs of terminal care and aro-
matase inhibitors. CONCLUSIONS: CYP2D6 Genetic testing in combination with
hormone treatment for early breast cancer patientsmay be economically attractive
in the current setting. Future research is required to determine efficacy of extended
tamoxifen (more than 5 years) treatment, the rate of progression to a more ad-
vanced cancer health state and adverse events by CYP2D6 polymorphism.
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OBJECTIVES: To develop a cost-effectiveness analysis of LC versus TC in the treat-
ment of metastatic breast cancer ErBb2 after progression to one regime of
trastuzumab. METHODS: A Markov model was designed with one week length
cycles, two years time horizon and two stages: Free of Progression and Progression.
The analysis was conducted from the perspective of the Mexican public Health
System for patients who had progressed to the first scheme of trastuzumab
(around 900 patients). Efficacy data for this specific population was based on and
ad-hoc sub analysis reported by Cameron 2010 for LC: 0.50, p0.001 and per proto-
col population reported by Minckwitz 2009 for TC: 0.69, p0.034. Baseline analysis
used time to progression for monotherapy reported by Minckwitz and an univari-
ate sensitivity analysis was run with monotherapy results by Cameron. Govern-
ment prices were used for capecitabine (2000 mg/m2/day), lapatinib (1250 mg/day)
and trastuzumab (2mg/kg/week). One chemotherapy session costwas added every
three weeks in the trastuzumab arm. Results are reported in US dollars. RESULTS:
Cost-effectiveness ratio for LC and TC was $650.82 and $756.86 respectively. LC
group had an average incremental effectiveness of 7.47 weeks free of progression
and an incremental cost of $371.74 (ICER$49.74). The acceptability curve showed
that with a willingness to pay above $480.16 per free of progression week the 100%
of cases would be cost-effective. In the univariate sensitivity analysis the LC group
gained 8.04 weeks free of progression with an incremental cost of $225.60 com-
pared to TC (ICER$28.04). CONCLUSIONS: According to this analysis the LC group
gained 7.47weeks free of progressionwith an extra cost of $371.74 ($49.74 perweek)
compared to TC. The LC grouphad a lowermonthly cost of treatment ($650.82) than
TC ($756.86). LC is cost-effective with a willingness to pay above $480.16 per extra
progression free week.
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OBJECTIVES: To assess the cost-effectiveness of a single-dose Pegfilgrastim 6mg
subcutaneously at day 5 versus Filgrastim 5g/kg/day subcutaneously from D5 to
resolution of neutropenia (absolute neutrophil count ANC0.5G/L) after stem cell
reinfusion in adult patients with lymphoma or myeloma, which is one of the first
studies on observational data.METHODS: Cost-effectiveness was assessed within
an open, multicentre randomized phase-II trial. The time horizon was 100/10
days from stem cell transplantation. Cost computation, using a microcosting ap-
proach focused on inpatient and home care, and cost distributions between the
two treatment armswere compared using theMann-Whitney test. Multiple regres-
sion analyses were performed in order to identify cost drivers. Incremental cost-
effectiveness ratios (ICERs) were based on the number of days with 1) febrile neu-
tropenia (ANC0,5G/L and temperature 38°C), 2) neutropenia (ANC1.0G/L), 3)
thrombopenia (platelets20.0G/L), and 4) temperature (38°C). Uncertainty
around ICERs was evaluated using Filler’s method and Monte Carlo simulations.
RESULTS: 151 patients were enrolled (October 2008/September 2009). One was not
evaluable due to missing data. Average total costs reached 25,024€ (SD 9,945€) for
Pegfilgrastim (n74) versus 28,700€ (SD 25,165€) for Filgrastim (n76), with 22,061€ (SD
8,101€) versus 25,165€ (SD 16,572€) for hospitalisation; 1,217€ (SD 2,039€) versus 1,444€
(SD 3,367€) for anti-infectious treatment; 1,106€ (SD 1,132€) versus 1,329€ (SD 2,598) for
transfusions; and 639€ (SD 89€) versus 762€ (SD 230€,) for growth factors, respectively.
The cost of growth factors significantly decreased with Pegfilgrastim, in women, in
patients with previous induction. Pegfilgrastim dominated Filgrastim for number of
days with febrile neutropenia, neutropenia, thrombopenia, and temperature. On the
two-fold basis of their cost and their medical effectiveness, Pegfilgrastim dominated
Filgrastim based on the 82% confidence region. CONCLUSIONS: From these results
there seems to be no restriction to the prescription of Pegfilgrastim in lymphoma and
myelomapatients after high-dose chemotherapy and autologous stemcell transplan-
tation.
PCN61
COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR
EARLY STAGE OF HER2-POSITIVE BREAST CANCER
Nguyen TTT1, Yagudina R2, Kulikov AU3
1First Moscow State Medical University named Sechenov, Moscow, Russia, 2Laboratory of
Pharmacoeconomics, Moscow Medical Academy, Moscow, Russia, 3Moscow Medical Academy,
Moscow, Russia
OBJECTIVES: Evaluate the cost-effectiveness of addition one-year adjuvant trastu-
zumab therapy to standard adjuvant chemotherapy in treatment of HER2 breast
cancer (BC) early stage from a societal perspective in a Russian setting.METHODS:
We used a Markov state transition model to simulate adjuvant trastuzumab treat-
ment in a hypothetical cohort of early breast cancer patients for lifetime horizon.
Patients were treated with a combination of chemotherapy and 1-year trastu-
zumab therapy (HT  T) or only with chemotherapy (HT). The transition probabil-
ities between states in the Markov model, the effectiveness and usefulness of
treatment were obtained from clinical studies HERA, 2005 and other published
data. Costs for each state Markovmodel based on the standard treatment of breast
cancer in Russia. Data about cost of medical services and drugs are received from
the price-list of out-patient medical aid in clinic MMA of I.M.Sechenov 10.01.2010,
site minzdravsoc.ru//medicine and other accessible electronic resources. Costs,
effectivenesses, utilities were discounted at 3%. Sensitivity analysis for key param-
eters in the model was conducted. RESULTS: On the basis of Markov model with
lifetime horizon, CTT has an incremental cost-effectivesness ratio (ICER) of
860.704 roubles per LYG and incremental cost-utility ratio (ICUR) of 986.015 roubles
per QALY. According to our threshold analysis, additional expenses on additional
QALY are in a comprehensible range (825.0001.650.000 roubles), that has allowed
to make the conclusion about an acceptability of one-year use trastuzumab in
treatment of patients HER2  breast cancer at early stages. Sensitivity analysis
showed thatmajor factors influencing cost-effectiveness and cost-utility ratios are
survival gain, price of trastuzumab, discount rates. CONCLUSIONS: The combina-
tion 1-year adjuvant trastuzumabwith standard chemotherapy ismore cost-effec-
tive and cost-useful in comparison with standard chemotherapy for patients HER2
 breast cancer at early stages.
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OBJECTIVES: The cost-effectiveness of different Human Papillomavirus (HPV) vac-
cination programmes was already confirmed throughout a large body ofmodelling
studies. An excess of uncertainty associated with the main parameters of com-
monly utilized models can be observed. The aim of this study was to assess the
cost-effectiveness of a quadrivalent-based multi-cohort HPV vaccination strategy
using a statistical Bayesian approach. METHODS: A full Bayesian Markov model
was used, where all unknown quantities were associated with suitable probability
distributions reflecting the state of science currently available. These distributions
were updated by the observation of any Italian available data, and uncertainty was
propagated through the entire model with a Markov Chain Monte Carlo procedure.
The model was calibrated using age-specific incidence of invasive cervical cancer
data. RESULTS: Base case (2 cohorts of girls aged 12 and 15 years) and other multi-
cohort vaccination strategies under evaluation (3 and 4 cohorts) were cost-effective
with a discounted cost per QALY gained corresponding to €12,013 (95% range €2,364
- €22,481), €13,232 (95% range €4,432 - €22,939), and €15,890 (95% range €7,179 -
€25,139) for vaccination programmes based on 2, 3 and 4 cohorts, respectively. The
overall expected effect of vaccination seems to be linked with the number of co-
horts targeted. With a multi-cohort vaccination the combined reduction of HPV-
related events occurred progressively early (range 3 – 6.5 years) compared with the
vaccination of a single cohort. The analysis of the expected value of information
showed that the uncertainty was always kept at a low level among different multi-
cohort strategies. The cost associated with the achievement of the expected value
of information ranged between €9 and €13 per patient. CONCLUSIONS: The qua-
drivalent-based multi-cohort HPV vaccination programme can provide excellent
value for money spent and the Bayesian expected value-of-information analysis
provides the most appropriate and feasible representation of this program’s true
value.
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